Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America.

@article{Torres2019UpdatedRO,
  title={Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America.},
  author={Jaime R. Torres and Luiza Helena Falleiros-Arlant and Bradford D. Gessner and Isabelle Delrieu and Mar{\'i}a Luisa Avila-Aguero and H I G Giambernardino and Abiel Mascare{\~n}as and Jos{\'e} Brea and Constanza Torres and J M Castellanos-Martinez},
  journal={Vaccine},
  year={2019}
}
4 Citations

Cost-effectiveness of Dengue Vaccination in Puerto Rico

TLDR
Estimates of the cost-effectiveness and benefits of the pre-vaccination screening and vaccination of seropositive persons in Puerto Rico and the ratio of the averted hospitalizations among all vaccinees to additional hospitalization among DENV-naive vaccinees was estimated to be 19 (13-24).

Reemerging Viral Infections: Implications of Lack of Vaccination

TLDR
This chapter reviews reemerging viral infections with primary and secondary cutaneous manifestations and discusses the factors spurring the anti-vaccination movement and the obstacles healthcare faces in abating its consequences.

Nervous System Manifestations of Arboviral Infections

TLDR
Some of the most frequent and emerging neuro-invasive arboviral infections, spectrum of neurologic disorders including encephalitis, meningitis, myelitis or poliomyelitis, acute demyelinating encephalomyeliitis, Guillain-Barré syndrome, and ocular syndromes are described.

Factors influencing healthcare seeking in patients with dengue: Systematic review

TLDR
A systematic review aimed to synthesise the factors influencing healthcare seeking of patients with dengue and form a comprehensive framework for interventions to improve healthcare seeking for d Dengue.

References

SHOWING 1-10 OF 34 REFERENCES

Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure

TLDR
Vaccination with CYD-TDV following serological screening could have a positive impact in certain epidemiological settings, provided that screening is highly specific, at least moderately sensitive, and inexpensive.

A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America.

  • E. SartiM. L'Azou R. L. Ochiai
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2016

Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews

Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards

TLDR
The best methods of surveillance in general, the stakeholders in d Dengue surveillance, and the steps from mosquito bite to reporting of a dengue case are described to explore how best to carry out dengu surveillance.

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

TLDR
CYD‐TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated people who had not been exposed to d Dengue.

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

TLDR
Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years ofAge was lower in the vaccine group than in the control group.

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.

Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials

TLDR
These exploratory findings show that CYD-TDV does not induce a particular immune profile versus placebo, corroborating the clinical profile observed.